“Our proprietary intranasal platform has the potential to enhance drug delivery bioavailability. We believe that intranasal delivery has the potential to improve patient outcomes by providing a ...

The intranasal delivery method of Naloxone presents several benefits, such as ease of use and the elimination of the need for medical professionals during administration, making it more accessible ...

Polyrizon (PLRZ) announced that it has signed a non-binding Letter of Intent with a biotech company focused on psychedelic-derived ...

Virpax Pharmaceuticals, Inc. (Nasdaq: VRPX) has announced its plans to explore utilizing Molecular Envelope Technology (MET) ...

This collaboration emphasizes the growing potential of intranasal drug delivery in the psychedelic medicine space, offering an innovative approach to enhancing bioavailability, efficacy ...

Polyrizon Ltd. (Nasdaq: PLRZ) (the "Company" or "Polyrizon"), a development stage biotech company specializing in the development of innovative intranasal ...

This agreement aims to leverage Polyrizon's proprietary platform to optimize the delivery of innovative psychedelic treatments for therapeutic use. This collaboration emphasizes the growing potential ...

In collaboration with Professor Fabio Sonvico from the University of Parma, the company is evaluating its Trap and Target™ (T&T) platform’s potential to enhance the drug’s nasal delivery. The ongoing ...

Theglobal marketfor Naloxone is rapidly growing, with intranasal delivery offering significant advantages such as ease of use and greater accessibility for emergency response. Polyrizon is ...